Fate Therapeutics

SAN DIEGO — September 9, 2026 Fate Therapeutics, Inc. announced that new clinical data for its off-the-shelf anti-CD19 CAR...

San Diego, California — August 14, 2026 Fate Therapeutics, Inc. has initiated the potentially registrational RECLAIM-LN Phase 2 clinical...

SAN DIEGO, July 6, 2026 Fate Therapeutics announced that preliminary clinical data from its investigational FT819 off-the-shelf CD19-targeting CAR...